U.S. drug tariffs disrupt global pharma and outsourcing markets
PENNSYLVANIA, UNITED STATES — The United States’ government’s sweeping 100% tariff on imported branded and patented pharmaceuticals is disrupting the global pharmaceutical industry, forcing multinational drugmakers and their outsourcing partners to rethink research, manufacturing, and supply strategies.
According to a Clinical Leader thought leadership piece by Mathini Ilancheran, senior delivery lead for research and R&D at Beroe Inc., the new policy applies to all branded or patented drugs entering the U.S., unless manufacturers are actively building domestic production facilities.
Under a mid-2025 trade deal, the European Union and Japan secured a tariff cap of about 15%, while the United Kingdom and Switzerland remain fully exposed. Generic drugs are exempt from the new tariffs.
Pharma supply chains brace for cascading disruptions
“This policy is more than a price shock. It introduces structural disruption across the drug development life cycle, affecting global supply chains, multinational pharma firms, and critical partners,” Ilancheran said.
Ilancheran’s analysis highlights that every stage of the pharmaceutical process—from early R&D to post-approval packaging—is feeling the strain.
Branded reagents, comparator drugs, and clinical trial materials sourced from high-tariff regions face sharp price hikes and logistical delays.
“Without visibility, high-risk SKUs from Switzerland and the U.K. could slip into trials or supply chains unnoticed,” Ilancheran noted, emphasizing the importance of detailed mapping of imports by country of origin, branded status, and finishing site.
The impact on U.S. clinical research could be especially significant. “Trials dependent on imported materials now face higher drug import prices and customs bottlenecks,” she said. This means longer lead times, inflated budgets, and slower patient recruitment.
To adapt, pharmaceutical firms are securing tariff-protected capacity in the U.S. and EU, revising supplier contracts to include tariff clauses, and diversifying their supplier networks. Ilancheran warned that “domestic CDMO and packaging capacity will tighten within 12 to 18 months,” emphasizing the value of early action.
Outsourcing sector faces global realignment
The policy’s ripple effects are also reshaping the global outsourcing ecosystem.
Contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and central labs—all vital to drug development—must now adjust sourcing models, verify supplier declarations, and secure dual sources for critical components.
Ilancheran said the 100% tariff policy marks “a turning point for global pharma supply chains,” urging companies to treat it as both a compliance challenge and an opportunity for resilience.
From a broader perspective, this disruption may spark a new phase of regionalization in pharmaceutical outsourcing.
As big pharma diversifies away from high-tariff markets like the U.K. and Switzerland, emerging economies with robust manufacturing capabilities—including India, Singapore, and other Southeast Asian countries—could rise as preferred partners.
For outsourcing players, this shift represents a chance to deepen global collaboration while building more flexible, transparent, and tariff-proof supply chains for the future.
